Loading...
Loading...
Browse drug and medication recalls including prescription drugs, OTC medications, and supplements. Stay informed about pharmaceutical safety alerts.
Marketed Without An Approved NDA/ANDA: Miracle Diet 30 was found to contain undeclared phenolphthalein, a drug product once contained in over-the-counter laxatives but was taken off the U.S. market due to safety concerns, making this product an unapproved drug.
Presence of Particulate Matter: particulate matter identified as iron oxide, was found embedded in the neck of glass vials.
This recall to replace involves bottle caps for Temodar and Temozolomide (generic) capsules, an oral chemotherapy drug. The capsules were distributed in 5- and 14-count brown glass bottles that have white plastic child-resistant caps. A white label affixed to the bottle has the word "Temozolomide" printed in black lettering.
Marketed Without An Approved NDA/ANDA: Dietary supplements contains undeclared sibutramine, desmethylsibutramine and phenolphthalein based on FDA sampling.
Marketed Without an Approved NDA/ANDA: FDA sampling and analysis confirmed the presence of sibutramine and desmethylsibutramine.
This recall involves "Well at Walgreens" Multivitamin Women 50+ tablets. The white plastic bottles contain 200 multivitamin tablets. "Well at Walgreens Multivitamin Women 50+" is printed on the bottle's white and silver label. A yellow band at the top of the label states "Value Size." UPC number 3-11917-17262-0 and one of the following lot numbers 000001 (EXP 9/2016), 000002 (EXP 12/2016) or 000003 (EXP 11/2016) are printed on the back of the bottles on a white label.
This recall involves all 60-count bags of cherry flavor Soft Chews Iron with Vitamin C dietary supplements. The pink re-sealable bag has an image of cherries and a leaf on the front of the package. "Soft Chews Iron with Vitamin C," "Cherry flavor," "Bariatric Fusion," "60 Soft Chews" and "Dietary Supplement" are also on the front. Lot number 14191C2 is printed near the bottom of the back of the bags being recalled.
This recall involves bottles of 100ct Panadol Advance pain relievers. The medicine was sold in white containers with a blue label, inside a blue box. "Panadol" and "Advance" are printed on the label. Lot numbers and dates codes are located on the left side panel of the box and on the left side of the label on the bottle, near the bar code. Lot numbers and date codes included in the recall are: Lot number: 14241, expiration date: 02/2015 Lot number: 14002, expiration date: 10/2014 Lot number: 13881, expiration date: 09/2014 Lot number: 13801, expiration date: 09/2014
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.
Lack of Assurance of Sterility; All lots of sterile products compounded by the pharmacy within expiry are subject to this recall. This recall is initiated due to concerns associated with quality control procedures observed during a recent FDA inspection.